Theravance Biopharma
Market Cap
€1.6b
Last Updated
2020/05/25 23:19 UTC
Data Sources
Company Financials +
Executive Summary
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Slightly overvalued with limited growth.
Share Price & News
How has Theravance Biopharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 0TB's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-0.8%
0TB
0.6%
DE Pharmaceuticals
2.2%
DE Market
1 Year Return
55.9%
0TB
18.1%
DE Pharmaceuticals
-3.9%
DE Market
Return vs Industry: 0TB exceeded the German Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: 0TB exceeded the German Market which returned -4.6% over the past year.
Shareholder returns
| 0TB | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.8% | 0.6% | 2.2% |
| 30 Day | -6.7% | 0.7% | 8.0% |
| 90 Day | 15.7% | 2.6% | -9.6% |
| 1 Year | 55.9%55.9% | 21.8%18.1% | -2.3%-3.9% |
| 3 Year | -25.2%-25.2% | 28.8%14.0% | -7.6%-14.8% |
| 5 Year | 98.6%98.6% | 30.4%7.9% | -0.3%-12.9% |
Price Volatility Vs. Market
How volatile is Theravance Biopharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Theravance Biopharma undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 0TB (€25) is trading below our estimate of fair value (€81.24)
Significantly Below Fair Value: 0TB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 0TB is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: 0TB is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 0TB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 0TB has negative assets, so we can't compare its PB Ratio to the XE Pharmaceuticals industry average.
Next Steps
Future Growth
How is Theravance Biopharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
48.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0TB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0TB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0TB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0TB's revenue (32.9% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: 0TB's revenue (32.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0TB's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Theravance Biopharma performed over the past 5 years?
-4.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 0TB is currently unprofitable.
Growing Profit Margin: 0TB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 0TB is unprofitable, and losses have increased over the past 5 years at a rate of -4.9% per year.
Accelerating Growth: Unable to compare 0TB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0TB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.2%).
Return on Equity
High ROE: 0TB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Next Steps
Financial Health
How is Theravance Biopharma's financial position?
Financial Position Analysis
Short Term Liabilities: 0TB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 0TB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 0TB has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: 0TB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0TB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 0TB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Theravance Biopharma's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 0TB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 0TB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 0TB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 0TB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 0TB's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.2yrs
Average management tenure
CEO
Rick Winningham (59yo)
5.92yrs
Tenure
US$5,932,412
Compensation
Mr. Rick E. Winningham has been the Chairman and Chief Executive Officer at Theravance Biopharma, Inc. since its spin-off from Theravance, Inc. since July 2013 and since June 2014 respectively. Mr. Winning ...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD5.93M) is above average for companies of similar size in the German market ($USD1.50M).
Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 5.92yrs | US$5.93m | 1.37% $21.8m | |
| Senior VP & CFO | 0.92yr | US$3.76m | 0.021% $325.2k | |
| Executive VP | 5.67yrs | US$2.47m | 0.11% $1.8m | |
| Senior VP of Clinical Development & Chief Medical Officer | 5.42yrs | US$2.46m | 0.50% $7.9m | |
| Senior VP & Chief Commercial Operations Officer | 4.17yrs | US$2.46m | 0.35% $5.5m | |
| Senior Vice President of Technical Operations | 2.75yrs | no data | 0.32% $5.1m | |
| Vice President of Corporate Communications & Investor Relations | no data | no data | no data | |
| Vice President of Sales & Marketing | 1.83yrs | no data | no data | |
| Senior VP of Human Resources | 4.17yrs | no data | no data | |
| Senior Vice President of Research & Translational Science | 4.17yrs | US$2.40m | 0.56% $8.9m |
4.2yrs
Average Tenure
49yo
Average Age
Experienced Management: 0TB's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 5.92yrs | US$5.93m | 1.37% $21.8m | |
| Lead Independent Director | 6.08yrs | US$393.88k | 0.092% $1.5m | |
| Independent Director | 5.92yrs | US$353.38k | 0.042% $658.2k | |
| Independent Director | 6.58yrs | US$337.88k | 0.38% $6.0m | |
| Independent Director | 6.58yrs | US$381.88k | 0.14% $2.2m | |
| Independent Director | 6.58yrs | US$337.88k | 0.069% $1.1m | |
| Independent Director | 5.92yrs | US$359.88k | 0.065% $1.0m | |
| Independent Director | 4.58yrs | US$359.88k | 0.054% $859.8k | |
| Independent Director | 5.08yrs | US$355.88k | 0.065% $1.0m | |
| Independent Director | 2.25yrs | US$339.88k | 0.040% $627.9k |
6.0yrs
Average Tenure
66yo
Average Age
Experienced Board: 0TB's board of directors are considered experienced (6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.4%.
Top Shareholders
Company Information
Theravance Biopharma, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Theravance Biopharma, Inc.
- Ticker: 0TB
- Exchange: DB
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.727b
- Listing Market Cap: US$1.586b
- Shares outstanding: 63.09m
- Website: https://www.theravance.com
Number of Employees
Location
- Theravance Biopharma, Inc.
- Ugland House
- South Church Street
- George Town
- Grand Cayman
- KY1-1104
- Cayman Islands
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TBPH | NasdaqGM (Nasdaq Global Market) | Yes | Common Shares | US | USD | May 2014 |
| 0TB | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | May 2014 |
Biography
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn’s disease. In addition, the company’s product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Mylan Ireland Limited, Janssen Biotech, Inc., Alfasigma S.p.A, Trek Therapeutics, PBC, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/25 23:19 |
| End of Day Share Price | 2020/05/25 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.